The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.
The newer quinolone antibiotics, including levofloxacin, moxifloxacin, and gatifloxacin, offer coverage of the likely pathogens in community-acquired pneumonia (CAP) and have been shown to be safe and effective treatments for CAP. Two of these agents, levofloxacin and gatifloxacin, have pharmacokinetic and antibacterial properties that are similar in both oral and intravenous formulations. As such, they may be excellent candidates for transition therapy involving early switch from intravenous to oral therapy followed by early hospital discharge for patients with CAP
Press
R A
RA
New York University Medical Center, New York 10016, USA.
D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D019540:Area Under Curve; D001682:Biological Availability; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D024841:Fluoroquinolones; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008657:Metabolic Clearance Rate; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology; D011485:Protein Binding
D000890:Anti-Infective Agents; D024841:Fluoroquinolones